Abstract:Butyrophilin 1A1 (BTN1A1) is a novel immune checkpoint protein belonging to the butyrophilin family and is expressed on immune cells such as macrophages, B cells, or activated CD8 T cells and in human tumors. Our results indicate that BTN1A1 and PD-L1 expression are mutually exclusive in various human solid tumors. Furthermore, it was observed that BTN1A1 had a significantly higher detection level than PD-L1 in cancer patient samples. We have reported that BTN1A1 plays an immunomodulatory role in T cell activation and proliferation. BTN1A1 inhibited the proliferation of T cells that are activated by anti-CD3 and anti-CD28 antibodies in vitro. Overexpression of BTN1A1 in PC3 cells also inhibits T cell-mediated killing of cancer cells. BTN1A1 is a bona fide immune checkpoint inhibitor and has anti-tumor activity in a human immune setting. BTN1A1 represents a novel cancer immunotherapy target that goes beyond the low expression levels of PD-1/PD-L1 in tumors. BNT1A1 is an immune checkpoint and cell membrane protein that, together with its binding partners, serves as a starting point for signaling pathways. The BNT1A1 complex, which has various abilities by combining with a specific partner, plays a vital role as an immune checkpoint. In this study, we identified binding partners of BTN1A that regulate immune activity in a mutually interaction relationship with BTN1A1 in various ways. We identified binding partners for the extracellular domain of human BTN1A1 using cell microarrays from Retrogenix (Whaley Bridge, UK). Through this screening approach, we found that BTN1A1 binds to galectin-1 (Gal1), galectin-9 (Gal9), and neuropilin 2 (NRP2). These three putative binding partners could specifically bind to wild-type BTN1A1 but not to this protein's unglycosylated (2NQ) form. Of these three targets, immunoprecipitation and Biacore binding assays revealed that Gal9 exhibited the greatest affinity for human BTN1A1. Since Gal9 is a known PD-1 and TIM3 binding protein, we predicted the potential formation of a BTN1A1/Gal9/PD-1 or BTN1A1/Gal9/TIM3 complex. Indeed, it reveals that immunoprecipitation and confocal microscopy assays performed using cells expressing Myc-tagged versions of these four proteins demonstrated the formation of BTN1A1/Gal9, PD-1/Gal9, TIM3/Gal9, BTN1A1/Gal9/TIM3, and BTN1A1/Gal9/PD-1 complexes. In T cell activation assay using these complexes, when present BTN1A1 alongside the complex inhibits activated T cells. As high Gal9 expression levels are correlated with poor prognosis in multiple cancers, our results highlight this BTN1A1-Gal9-PD-1 or BTN1A1-Gal9-TIM3 axis as a novel therapeutic target for immunotherapeutic drug development. Citation Format: Seung Hoon Lee, Young-Seung Kim, Chunai Wu, Andrew H Park, Stephen S. Yoo. BTN1A1 regulates T cell-mediated cancer immunotherapy by interacting with Galectin-9, PD-1, and TIM3 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 1372.

Butyrophilin 2A2 promotes T cell immunoregulation by enhancing CD45 phosphatase activity within the immune synapse

BTNL2, a Butyrophilin-Like Molecule That Functions to Inhibit T Cell Activation.

Otud7b facilitates T cell activation and inflammatory responses by regulating Zap70 ubiquitination

Shp-2 Phosphatase Negatively Regulates The Trif Adaptor Protein-Dependent Type I Interferon And Proinflammatory Cytokine Production

Vγ9Vδ2 T cells recognize butyrophilin 2A1 and 3A1 heteromers

Cis Interactions Between CD2 and Its Ligands on T Cells Are Required for T Cell Activation

N-terminal ectodomain of BTNL2 inhibits T cell activation via a non-canonical interaction with its putative receptor that results in a delayed progression of DSS-induced ulcerative colitis

Abstract 1643: BTN1A1: a novel immune checkpoint for cancer immunotherapy beyond the PD-1/PD-L1 axis

BTN2A1 targeting reprograms M2-like macrophages and TAMs via SYK and MAPK signaling

2B4 (CD244) induced by selective CD28 blockade functionally regulates allograft-specific CD8+ T cell responses

Butyrophilin 3A (BTN3A, CD277)-specific antibody 20.1 differentially activates Vγ9Vδ2 TCR clonotypes and interferes with phosphoantigen activation

Protein Tyrosine Phosphatase CD45 As an Immunity Regulator and a Potential Effector of CAR-T therapy

Abstract 1372: BTN1A1 regulates T cell-mediated cancer immunotherapy by interacting with Galectin-9, PD-1, and TIM3

BTN2A2 protein negatively regulates T cells to ameliorate collagen-induced arthritis in mice

Phosphoantigens Glue Butyrophilin 3A1 and 2A1 to Activate Vγ9Vδ2 T Cells

BTN2A2-Ig protein inhibits the differentiation of pathogenic Th17 cells and attenuates EAE in mice

The Tyrosine Phosphatase Activity of PTPN22 Is Involved in T Cell Development via the Regulation of TCR Expression

Attenuation of Apoptosis Underlies B Lymphocyte Stimulator Enhancement of Humoral Immune Response

Protein Tyrosine Phosphatase SHP-1 Modulates T Cell Responses by Controlling Cbl-b Degradation

Targeting BTN2A1 enhances Vγ9Vδ2 T-cell effector functions and triggers tumor cell pyroptosis

BTNL2, A Novel Inhibitory Molecular